Startups

Beaconcure

Boston, Massachusetts, United States · Tel Aviv, Israel

Beaconcure is a clinical-development software company whose Verify platform applies AI and automation to review statistical clinical-trial outputs, including tables, listings and figures, and to support traceability, quality assurance and submission workflows for biopharmaceutical companies and contract research organisations. The issuer describes the business as founded in2016; its exact US reporting corporation Beaconcure Inc., CIK1894780, was incorporated in Delaware in2021, so platform founding and US legal-entity formation are distinguished. Current public leadership includes CEO Seth Houston, appointed effectiveJuly13,2026, co-founder/COO Ilan Carmeli, finance/operations VP Michael Tober, CTO Adam Heunis and global sales VP Chuck Gelb. The published board includes Anne Whitaker as chairperson (called Interim Chair in July2026), Todd Holmes, Noam Stern, Houston and Carmeli; advisers Névine Zariffa and Irving Dark are listed separately. Former CEO/co-founder Yoran Bar, later officer Christine Oliver and dated prior directors/advisers are preserved as historical affiliations. Verify supports analysis and documentation for regulatory submissions; that does not establish FDA approval of Beaconcure software, clinical efficacy or approval of a drug merely because a customer uses it. The company announced actualUSD14M SeriesB closure onJune13,2023 led by NewVale Capital with unnamed existing investors. Its March2023 SEC notice reported9.89M sold toward the same14M offering, not a second additive raise. Separate SEC disclosures report2.04M sold toward an ongoing4M offering in2021, and a fully soldUSD14,989,997 equity offering inJanuary2025 whose primary disclosed stage/buyers are unpublished. Filing-signature and first-sale dates are not guessed final closing days. Noam Stern is explicitly described by the issuer as a lead investor from inception; exact historical ticket, vehicle and financing details are undisclosed. Pfizer is a product-development partner, not an inferred equity investor. Secondary-only early seed/grant figures are queued for primary verification, not entered as paid cash.

Founded 2016